Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

CLLS has been the topic of several other research reports. Oppenheimer dropped their target price on shares of Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, June 12th. JMP Securities restated a “market outperform” rating and issued a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st.

Cellectis Trading Up 2.3 %

NASDAQ:CLLS opened at $2.27 on Tuesday. The company’s 50 day moving average price is $2.16 and its 200-day moving average price is $2.44. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The stock has a market cap of $126.17 million, a price-to-earnings ratio of -1.76 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $9.50 million for the quarter, compared to analysts’ expectations of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. On average, equities research analysts forecast that Cellectis will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Several institutional investors have recently made changes to their positions in CLLS. Long Focus Capital Management LLC grew its position in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. XTX Topco Ltd bought a new stake in Cellectis during the second quarter valued at approximately $29,000. Principal Financial Group Inc. grew its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Finally, Baillie Gifford & Co. grew its position in Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after buying an additional 10,605 shares during the period. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.